Clinical usefulness of FDG-PET in oncology

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The clinical diagnosis of tumors is mainly performed using conventional radiography, CT, MRI, and ultrasonography, which provide anatomic and morphologic information. On the other hand, nuclear medicine imaging, which exploits the biochemical aspects of tissue, is considered to be useful for the characterization of tumors but is still clinically underutilized. Positron emission tomography (PET) with 2-deoxy-2-[18F] fluoro-D-glucose(FDG), an in-vivo imaging method that measures glucose metabolism, has been used to detect tumors with increased glucose metabolism. Over the past 20 years, numerous reports have demonstrated the usefulness of FDG-PET in diagnosing tumors, although FDG-PET has only been performed at a small number of institutions. Since FDG-PET has been shown to be superior to other morphologic imaging modalities in diagnosing tumors, FDG-PET has now become widespread at many institutions and has also been incorporated into the clinical pathways for disease management. FDG-PET is a safe and cost-effective method with several advantages over morphologic imaging and is already covered by many insurance companies in a variety of countries. This article discusses the current application of FDG-PET in oncology, especially regarding lung cancer, malignant lymphoma, and thyroid cancer. In addition, practical approaches for the clinical use of FDG-PET are discussed.

Original languageEnglish
Pages (from-to)414-420
Number of pages7
JournalNihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
Volume61
Issue number8
Publication statusPublished - Jan 1 2001

Fingerprint

Positron-Emission Tomography
Glucose
Neoplasms
Critical Pathways
Nuclear Medicine
Fluorodeoxyglucose F18
Disease Management
Insurance
Thyroid Neoplasms
Radiography
Ultrasonography
Lymphoma
Lung Neoplasms
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Clinical usefulness of FDG-PET in oncology. / Sasaki, Masayuki.

In: Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica, Vol. 61, No. 8, 01.01.2001, p. 414-420.

Research output: Contribution to journalReview article

@article{edaeb69079b7424c856e6ded2b10ce0e,
title = "Clinical usefulness of FDG-PET in oncology",
abstract = "The clinical diagnosis of tumors is mainly performed using conventional radiography, CT, MRI, and ultrasonography, which provide anatomic and morphologic information. On the other hand, nuclear medicine imaging, which exploits the biochemical aspects of tissue, is considered to be useful for the characterization of tumors but is still clinically underutilized. Positron emission tomography (PET) with 2-deoxy-2-[18F] fluoro-D-glucose(FDG), an in-vivo imaging method that measures glucose metabolism, has been used to detect tumors with increased glucose metabolism. Over the past 20 years, numerous reports have demonstrated the usefulness of FDG-PET in diagnosing tumors, although FDG-PET has only been performed at a small number of institutions. Since FDG-PET has been shown to be superior to other morphologic imaging modalities in diagnosing tumors, FDG-PET has now become widespread at many institutions and has also been incorporated into the clinical pathways for disease management. FDG-PET is a safe and cost-effective method with several advantages over morphologic imaging and is already covered by many insurance companies in a variety of countries. This article discusses the current application of FDG-PET in oncology, especially regarding lung cancer, malignant lymphoma, and thyroid cancer. In addition, practical approaches for the clinical use of FDG-PET are discussed.",
author = "Masayuki Sasaki",
year = "2001",
month = "1",
day = "1",
language = "English",
volume = "61",
pages = "414--420",
journal = "Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica",
issn = "0048-0428",
publisher = "Japan Radiological Society",
number = "8",

}

TY - JOUR

T1 - Clinical usefulness of FDG-PET in oncology

AU - Sasaki, Masayuki

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The clinical diagnosis of tumors is mainly performed using conventional radiography, CT, MRI, and ultrasonography, which provide anatomic and morphologic information. On the other hand, nuclear medicine imaging, which exploits the biochemical aspects of tissue, is considered to be useful for the characterization of tumors but is still clinically underutilized. Positron emission tomography (PET) with 2-deoxy-2-[18F] fluoro-D-glucose(FDG), an in-vivo imaging method that measures glucose metabolism, has been used to detect tumors with increased glucose metabolism. Over the past 20 years, numerous reports have demonstrated the usefulness of FDG-PET in diagnosing tumors, although FDG-PET has only been performed at a small number of institutions. Since FDG-PET has been shown to be superior to other morphologic imaging modalities in diagnosing tumors, FDG-PET has now become widespread at many institutions and has also been incorporated into the clinical pathways for disease management. FDG-PET is a safe and cost-effective method with several advantages over morphologic imaging and is already covered by many insurance companies in a variety of countries. This article discusses the current application of FDG-PET in oncology, especially regarding lung cancer, malignant lymphoma, and thyroid cancer. In addition, practical approaches for the clinical use of FDG-PET are discussed.

AB - The clinical diagnosis of tumors is mainly performed using conventional radiography, CT, MRI, and ultrasonography, which provide anatomic and morphologic information. On the other hand, nuclear medicine imaging, which exploits the biochemical aspects of tissue, is considered to be useful for the characterization of tumors but is still clinically underutilized. Positron emission tomography (PET) with 2-deoxy-2-[18F] fluoro-D-glucose(FDG), an in-vivo imaging method that measures glucose metabolism, has been used to detect tumors with increased glucose metabolism. Over the past 20 years, numerous reports have demonstrated the usefulness of FDG-PET in diagnosing tumors, although FDG-PET has only been performed at a small number of institutions. Since FDG-PET has been shown to be superior to other morphologic imaging modalities in diagnosing tumors, FDG-PET has now become widespread at many institutions and has also been incorporated into the clinical pathways for disease management. FDG-PET is a safe and cost-effective method with several advantages over morphologic imaging and is already covered by many insurance companies in a variety of countries. This article discusses the current application of FDG-PET in oncology, especially regarding lung cancer, malignant lymphoma, and thyroid cancer. In addition, practical approaches for the clinical use of FDG-PET are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0035408603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035408603&partnerID=8YFLogxK

M3 - Review article

C2 - 11524817

AN - SCOPUS:0035408603

VL - 61

SP - 414

EP - 420

JO - Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica

JF - Nippon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica

SN - 0048-0428

IS - 8

ER -